Department of Public Medicine and Social Security - Section of Infectious Disease University of Naples "Federico II", Italy.
Ther Clin Risk Manag. 2009 Feb;5(1):177-85. doi: 10.2147/tcrm.s3335. Epub 2009 Mar 26.
Recent literature is reviewed about treatment of chronic hepatitis B virus (CHB), focusing on tenofovir disoproxil fumarate (TDF; Viread((R))), among the nucleotide and nucleoside analogs. TDF pharmacokinetics and pharmacodynamics, activity in respect of hepatitis B virus (HBV) multi-drug-resistant mutations, efficacy in treatment-naïve and treatment-experienced patients, and side effects are described. The most predictive response factors to TDF therapy are discussed and all available combination therapies to optimize clinical outcome in the various patient profiles are analyzed, such as compensated and/or decompensated cirrhotic patients. The use of TDF in pregnancy, and prophylaxis after exposure to HBV and post-liver transplantation are also evaluated.
本文主要综述了慢性乙型肝炎病毒（CHB）的治疗药物，重点介绍了核苷酸类似物和核苷类似物中的替诺福韦酯（TDF；Viread((R))）。本文描述了 TDF 的药代动力学和药效学、对乙型肝炎病毒（HBV）多药耐药突变的作用、在初治和经治患者中的疗效以及副作用。讨论了预测 TDF 治疗反应的最相关因素，并分析了所有可用的联合治疗方案，以优化各种患者人群的临床转归，如代偿和/或失代偿性肝硬化患者。本文还评估了 TDF 在妊娠期间的应用、HBV 暴露后的预防以及肝移植后的应用。
